PMID- 28347819
OWN - NLM
STAT- MEDLINE
DCOM- 20170619
LR  - 20181202
IS  - 1090-2104 (Electronic)
IS  - 0006-291X (Linking)
VI  - 486
IP  - 4
DP  - 2017 May 13
TI  - Deferiprone attenuates inflammation and myocardial fibrosis in diabetic 
      cardiomyopathy rats.
PG  - 930-936
LID - S0006-291X(17)30603-4 [pii]
LID - 10.1016/j.bbrc.2017.03.127 [doi]
AB  - We attempted to investigate the therapeutic effects of deferiprone on DC rats and 
      explore the underlying mechanism. Total 24 6-week-old male Wistar rats (weighing 
      from 180 g to 220 g) were subjected to DC model construction and then randomly 
      divided to three groups (8 rats per group): DC group, DC + 50 mg, and DC + 100 mg 
      deferiprone treatment group. The 8 normal rats were considered as controls. After 
      deferiprone treatment for 20 weeks, the blood samples were collected for the 
      biochemical parameters test, including fasting glucose, HOMA-IR (homeostasis 
      model assessment of the insulin resistance), serum iron, ferritin and transferrin 
      saturation (TS). The oxidative stress was assessed by detecting the level of 
      malondialdehyde (MDA) and superoxide dismutase (SOD). Histopathologic changes 
      were determined by Masson's trichrome staining and electron microscopy imaging. 
      The expression levels of NF-kappaB (nuclear factor kappa B), COX2 (cytochrome c 
      oxidase), tenascin C, collagen IV were measured by RT-PCR and western blotting. 
      The expression of nitrotyrosine and MCP-1 (monocyte chemotactic protein 1) were 
      determined by immunohistochemistry. Deferiprone treatment reduced iron deposition 
      and IR in DC rats except for blood glucose. After deferiprone treatment, MDA 
      level was significantly decreased and SOD level was increased significantly. The 
      level of NF-kappaB, cyclooxygenase-2, tenascin C, collagen IV MCP-1 and nitrotyrosine 
      were significantly reduced. There was no significant difference in the effect of 
      deferiprone at 50 and 100 mg doses. Deferiprone showed therapeutic effects on DC 
      by regulating the pro-inflammatory and pro-fibrotic factors.
CI  - Copyright (c) 2017. Published by Elsevier Inc.
FAU - Zou, Chunbo
AU  - Zou C
AD  - Department of Nephrology, The First Affiliated Hospital of Harbin Medical 
      University, Harbin 150001, People's Republic of China.
FAU - Liu, Xiaogang
AU  - Liu X
AD  - Department of Nephrology, The First Affiliated Hospital of Harbin Medical 
      University, Harbin 150001, People's Republic of China. Electronic address: 
      xiaogangliuu@163.com.
FAU - Xie, Rujuan
AU  - Xie R
AD  - Department of Nephrology, The First Affiliated Hospital of Harbin Medical 
      University, Harbin 150001, People's Republic of China.
FAU - Bao, Yushi
AU  - Bao Y
AD  - Department of Nephrology, The First Affiliated Hospital of Harbin Medical 
      University, Harbin 150001, People's Republic of China.
FAU - Jin, Qing
AU  - Jin Q
AD  - Department of Nephrology, Heilongjiang Provincial Hospital, Harbin 150036, 
      People's Republic of China.
FAU - Jia, Xibei
AU  - Jia X
AD  - Department of Nephrology, The First Affiliated Hospital of Harbin Medical 
      University, Harbin 150001, People's Republic of China.
FAU - Li, Li
AU  - Li L
AD  - Department of Nephrology, The First Affiliated Hospital of Harbin Medical 
      University, Harbin 150001, People's Republic of China.
FAU - Liu, Ruichan
AU  - Liu R
AD  - Department of Nephrology, The First Affiliated Hospital of Harbin Medical 
      University, Harbin 150001, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20170324
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (Immunologic Factors)
RN  - 0 (Iron Chelating Agents)
RN  - 0 (Pyridones)
RN  - 0 (Reactive Oxygen Species)
RN  - 2BTY8KH53L (Deferiprone)
SB  - IM
EIN - Biochem Biophys Res Commun. 2018 Sep 5;503(2):1177. PMID: 29958699
MH  - Animals
MH  - Deferiprone
MH  - Diabetic Cardiomyopathies/*drug therapy/*immunology/pathology
MH  - Dose-Response Relationship, Drug
MH  - Endomyocardial Fibrosis/drug therapy/immunology/pathology
MH  - Immunologic Factors/immunology
MH  - Iron Chelating Agents/administration & dosage
MH  - Male
MH  - Myocarditis/*drug therapy/*immunology/pathology
MH  - Oxidative Stress/drug effects/immunology
MH  - Pyridones/*administration & dosage
MH  - Rats
MH  - Rats, Wistar
MH  - Reactive Oxygen Species/*immunology
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Deferiprone
OT  - Diabetic cardiomyopathy
OT  - Fibrosis
OT  - Inflammatory
EDAT- 2017/03/30 06:00
MHDA- 2017/06/20 06:00
CRDT- 2017/03/29 06:00
PHST- 2017/03/22 00:00 [received]
PHST- 2017/03/23 00:00 [accepted]
PHST- 2017/03/30 06:00 [pubmed]
PHST- 2017/06/20 06:00 [medline]
PHST- 2017/03/29 06:00 [entrez]
AID - S0006-291X(17)30603-4 [pii]
AID - 10.1016/j.bbrc.2017.03.127 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 2017 May 13;486(4):930-936. doi: 
      10.1016/j.bbrc.2017.03.127. Epub 2017 Mar 24.